PURPOSE: Subsequent malignant neoplasms (SMNs) are a dominant cause of morbidity and mortality in children treated for Hodgkin's disease (HD). We evaluated select demographic and therapeutic factors associated with SMNs, specifically gender and radiation dose. METHODS AND MATERIALS: A total of 930 children treated for HD at five institutions between 1960 and 1990 were studied. Mean age at diagnosis was 13.6 years, and mean follow-up was 16.8 years (maximum, 39.4 years). Treatment included radiation alone (43%), chemotherapy alone (9%), or both (48%). RESULTS: We found that SMNs occurred in 102 (11%) patients, with a 25-year actuarial rate of 19%. With 15,154 patient years of follow-up, only 7.18 cancers were expected (standardized incidence ratio [SIR] = 14.2; absolute excess risk [AER] = 63 cases/10,000 years). The SIR for female subjects, 19.93, was significantly greater than for males, 8.41 (p < 0.0001). After excluding breast cancer, the SIR for female patients was 15.4, still significantly greater than for male patients (p = 0.0012). Increasing radiation dose was associated with an increasing SIR (p = 0.0085). On univariate analysis, an increased risk was associated with female gender, increasing radiation dose, and age at treatment (12-16 years). Using logistic regression, mantle radiation dose increased risk, and this was 2.5-fold for female patients treated with more than 35 Gy primarily because of breast cancer. CONCLUSIONS: Survivors of childhood HD are at risk for SMNs, and this risk is greater for female individuals even after accounting for breast cancer. Although SMNs occur in the absence of radiation therapy, the risk increases with RT dose.
PURPOSE: Subsequent malignant neoplasms (SMNs) are a dominant cause of morbidity and mortality in children treated for Hodgkin's disease (HD). We evaluated select demographic and therapeutic factors associated with SMNs, specifically gender and radiation dose. METHODS AND MATERIALS: A total of 930 children treated for HD at five institutions between 1960 and 1990 were studied. Mean age at diagnosis was 13.6 years, and mean follow-up was 16.8 years (maximum, 39.4 years). Treatment included radiation alone (43%), chemotherapy alone (9%), or both (48%). RESULTS: We found that SMNs occurred in 102 (11%) patients, with a 25-year actuarial rate of 19%. With 15,154 patient years of follow-up, only 7.18 cancers were expected (standardized incidence ratio [SIR] = 14.2; absolute excess risk [AER] = 63 cases/10,000 years). The SIR for female subjects, 19.93, was significantly greater than for males, 8.41 (p < 0.0001). After excluding breast cancer, the SIR for female patients was 15.4, still significantly greater than for male patients (p = 0.0012). Increasing radiation dose was associated with an increasing SIR (p = 0.0085). On univariate analysis, an increased risk was associated with female gender, increasing radiation dose, and age at treatment (12-16 years). Using logistic regression, mantle radiation dose increased risk, and this was 2.5-fold for female patients treated with more than 35 Gy primarily because of breast cancer. CONCLUSIONS: Survivors of childhood HD are at risk for SMNs, and this risk is greater for female individuals even after accounting for breast cancer. Although SMNs occur in the absence of radiation therapy, the risk increases with RT dose.
Authors: J M Kaldor; N E Day; E A Clarke; F E Van Leeuwen; M Henry-Amar; M V Fiorentino; J Bell; D Pedersen; P Band; D Assouline Journal: N Engl J Med Date: 1990-01-04 Impact factor: 91.245
Authors: U Rühl; M Albrecht; K Dieckmann; H Lüders; H Marciniak; D Schellenberg; L Wickmann; W Dörffel Journal: Int J Radiat Oncol Biol Phys Date: 2001-12-01 Impact factor: 7.038
Authors: Andrea K Ng; M Patricia Bernardo; Edie Weller; Kendall H Backstrand; Barbara Silver; Karen C Marcus; Nancy J Tarbell; Jonathan Friedberg; George P Canellos; Peter M Mauch Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: Lois B Travis; Mary Gospodarowicz; Rochelle E Curtis; E Aileen Clarke; Michael Andersson; Bengt Glimelius; Timo Joensuu; Charles F Lynch; Flora E van Leeuwen; Eric Holowaty; Hans Storm; Ingrid Glimelius; Eero Pukkala; Marilyn Stovall; Joseph F Fraumeni; John D Boice; Ethel Gilbert Journal: J Natl Cancer Inst Date: 2002-02-06 Impact factor: 13.506
Authors: Graça M Dores; Catherine Metayer; Rochelle E Curtis; Charles F Lynch; E Aileen Clarke; Bengt Glimelius; Hans Storm; Eero Pukkala; Flora E van Leeuwen; Eric J Holowaty; Michael Andersson; Tom Wiklund; Timo Joensuu; Mars B van't Veer; Marilyn Stovall; Mary Gospodarowicz; Lois B Travis Journal: J Clin Oncol Date: 2002-08-15 Impact factor: 44.544
Authors: Andrea K Ng; M V Patricia Bernardo; Edie Weller; Kendall Backstrand; Barbara Silver; Karen C Marcus; Nancy J Tarbell; Mary Ann Stevenson; Jonathan W Friedberg; Peter M Mauch Journal: Blood Date: 2002-09-15 Impact factor: 22.113
Authors: Sarah S Donaldson; Melissa M Hudson; Kathleen R Lamborn; Michael P Link; Larry Kun; Amy Louise Billett; Karen C Marcus; Craig A Hurwitz; Jeffrey A Young; Nancy J Tarbell; Howard J Weinstein Journal: J Clin Oncol Date: 2002-07-15 Impact factor: 44.544
Authors: J M Kaldor; N E Day; P Band; N W Choi; E A Clarke; M P Coleman; M Hakama; M Koch; F Langmark; F E Neal Journal: Int J Cancer Date: 1987-05-15 Impact factor: 7.396
Authors: Jean L Nakamura; Connie Phong; Emile Pinarbasi; Scott C Kogan; Scott Vandenberg; Andrew E Horvai; Bruce A Faddegon; Dorothea Fiedler; Kevan Shokat; Benjamin T Houseman; Richard Chao; Russell O Pieper; Kevin Shannon Journal: Cancer Res Date: 2011-01-01 Impact factor: 12.701
Authors: Stephanie M Smith; Jennifer S Ford; William Rakowski; Chaya S Moskowitz; Lisa Diller; Melissa M Hudson; Ann C Mertens; Annette L Stanton; Tara O Henderson; Wendy M Leisenring; Leslie L Robison; Kevin C Oeffinger Journal: Cancer Causes Control Date: 2010-05-27 Impact factor: 2.506
Authors: Chaya S Moskowitz; Joanne F Chou; Suzanne L Wolden; Jonine L Bernstein; Jyoti Malhotra; Danielle Novetsky Friedman; Nidha Z Mubdi; Wendy M Leisenring; Marilyn Stovall; Sue Hammond; Susan A Smith; Tara O Henderson; John D Boice; Melissa M Hudson; Lisa R Diller; Smita Bhatia; Lisa B Kenney; Joseph P Neglia; Colin B Begg; Leslie L Robison; Kevin C Oeffinger Journal: J Clin Oncol Date: 2014-04-21 Impact factor: 44.544
Authors: G Mariscotti; M Durando; G Ghione; A Luparia; E Regini; C Alfieri; P P Campanino; P Gavarotti; E Brignardello; G Gandini Journal: Radiol Med Date: 2012-08-08 Impact factor: 3.469
Authors: Debra L Friedman; Lu Chen; Suzanne Wolden; Allen Buxton; Kathleen McCarten; Thomas J FitzGerald; Sandra Kessel; Pedro A De Alarcon; Allen R Chen; Nathan Kobrinsky; Peter Ehrlich; Robert E Hutchison; Louis S Constine; Cindy L Schwartz Journal: J Clin Oncol Date: 2014-10-13 Impact factor: 44.544
Authors: Burton E Appel; Lu Chen; Allen Buxton; Suzanne L Wolden; David C Hodgson; James B Nachman Journal: Pediatr Blood Cancer Date: 2012-07-27 Impact factor: 3.167
Authors: Grace Choi; Brian Huang; Emile Pinarbasi; Steve E Braunstein; Andrew E Horvai; Scott Kogan; Smita Bhatia; Bruce Faddegon; Jean L Nakamura Journal: Cancer Res Date: 2012-10-15 Impact factor: 12.701